MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
The pyramid welcomed a new player this month, although it was unable to unseat medtech titan Medtronic (NYSE:MDT) as the undisputed leader of the top 5. The company had a slew of headlines this month, especially amid the on-again-off-again ban on U.S. sales of its CoreValve replacement heart valves.
This month the 2nd-place spot went to Zimmer (NYSE:ZMH) and Biomet thanks to a merger that spurred a late-month spike in internet chatter. Covidien (NYSE:COV) came in 3rd with a recall, an acquisition and an FDA win.
The 4th-place spot went to Boston Scientific (NYSE:BSX) as it dealt with its own sales ban, Street-beating earnings, expansions overseas and more. St. Jude Medical (NYSE:STJ) brought up the rear with its own earnings, an FDA approval and a patent war with Volcano (NSDQ:VOLC).
Medtronic
- Medtronic under fire for payments in Scotland
- ACC 2014: Conflicts in renal denervation, competition in valves
- PAD: Medtronic’s In.Pact Admiral drug-eluting balloon bests Bard’s Lutonix at 6 months
- Medtronic puts fresh skin in distribution deals in Turkey and Missouri
- Paralysis: Medtronic’s spinal stimulator helps 4 more regain movement
- Medtronic wins CE Mark for Evera MRI SureScan ICD
- Hypertension: Docs turn on renal denervation
- FDA expands indication for Medtronic pacemakers, defibs
- TAVI: Court limits U.S. sales of Medtronic’s CoreValve
- TAVI: Medtronic vows to appeal CoreValve ban in patent loss to Edwards Lifesciences
- Diabetes: New warnings for Medtronic’s Paradigm insulin pumps
- Analogic wins FDA clearance for handheld Sonic Window vascular ultrasound
- TAVI: Judge chides Medtronic, Edwards offers consolation prize in infringement case
- Medtronic touts Endurant stent graft data
- Edwards Lifesciences decries Medtronic’s ‘scare tactics’ in CoreValve dispute
- Appeals court stays ban on Medtronic’s CoreValve device
- Bakris: Symplicity-3 a prologue for renal denervation
- Medtronic begins U.S. IDE trial for Evera SureScan MRI-safe ICD
- Medtronic celebrates 65 years with a Tweet
- Medtronic touts 5-year data on 3f Enable replacement heart valve
- Report: Anthem Blue Cross Blue Shield denies CoreValve coverage
Zimmer and Biomet
- Zimmer brings new ‘no profile’ Optio-C spine implant to the U.S.
- Biomet slashes Q3 losses, sales rise nearly 7%
- Ortho shakeup: Zimmer to acquire Biomet in deal worth $13.35 billion
- Zimmer beats The Street, alters 2014 forecast on Biomet buy
- The new face of ortho: Zimmer to take 2nd place with $13.4B Biomet buy
Covidien
- Going global: New AdvaMed chairman Almeida’s focus on medtech harmony around the world
- Covidien recalls Pipeline, Alligator brain aneurysm devices
- Report: Covidien pays $100M for New Wave Surgical
- Covidien lands FDA OK for camera-equipped feeding tube
- FDA: Covidien Pipeline recall is Class I
- Covidien beats The Street by 1¢ in Q2
Boston Scientific
- Boston Scientific’s lead-free S-ICD looks good in 1st real-world study
- Boston Scientific lands U.S., E.U. nods for Expect Slimline needle
- Boston Scientific’s lead-free S-ICD heads to Asia
- Boston Scientific makes new friends in Israel
- Boston Scientific launches Parkinson’s brain stim registry
- Plaintiffs look to remove pelvic mesh cases to Pennsylvania state court
- Appeals court vacates ban on Boston Scientific’s Guidezilla catheter
- Boston Scientific lands FDA approval for next-gen heart devices
- Boston Scientific launches trial for Acuity X4, Reliance 4-Front leads
- Boston Scientific beats estimates with Q1 earnings, but sales miss the mark
St. Jude Medical
- FDA approves St. Jude Medical’s Protégé spinal cord stimulator
- St. Jude Medical beats The Street, loses points anyway
- St. Jude Medical’s patent review bid denied in FFR war with Volcano